ALHC vs. AMGN: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ALHC and AMGN, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
AMGN stands out with 145.90 billion USD in market value—about 48.11× ALHC’s market cap of 3.03 billion USD.
ALHC’s beta of 1.33 points to much larger expected swings compared to AMGN’s calmer 0.50, suggesting both higher upside and downside potential.
| Symbol | ALHC | AMGN |
|---|---|---|
| Company Name | Alignment Healthcare, Inc. | Amgen Inc. |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Healthcare Plans | Drug Manufacturers - General |
| CEO | Mr. John E. Kao | Mr. Robert A. Bradway |
| Price | 15.33 USD | 271.34 USD |
| Market Cap | 3.03 billion USD | 145.90 billion USD |
| Beta | 1.33 | 0.50 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | March 26, 2021 | June 17, 1983 |
| ADR | No | No |
Performance Comparison
This chart compares the performance of ALHC and AMGN over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ALHC and AMGN based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- ALHC posts a negative P/E of -32.75, reflecting last year’s net loss, while AMGN at 24.60 signals healthy earnings.
- ALHC posts a negative forward PEG of -1.11, hinting at anticipated earnings decline, whereas AMGN at 7.08 has projections for stable or growing earnings.
| Symbol | ALHC | AMGN |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -32.75 | 24.60 |
| Forward PEG Ratio (TTM) | -1.11 | 7.08 |
| Price-to-Sales Ratio (P/S, TTM) | 1.01 | 4.28 |
| Price-to-Book Ratio (P/B, TTM) | 27.45 | 23.52 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 159.00 | 13.37 |
| EV-to-EBITDA (TTM) | -64.47 | 15.71 |
| EV-to-Sales (TTM) | 0.86 | 5.70 |
| EV-to-Free Cash Flow (TTM) | 136.01 | 17.82 |
Dividend Comparison
ALHC offers a 0% dividend yield, suggesting it may be reinvesting available cash back into the business for future growth, while AMGN provides a 3.41% dividend yield, giving investors a steady income stream.
| Symbol | ALHC | AMGN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 3.41% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ALHC and AMGN, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- AMGN is highly leveraged (debt-to-equity ratio 9.24), elevating both potential gains and risks, compared to ALHC at 0.07, which maintains a steadier capital structure.
- With negative EBIT (-2.98), ALHC cannot cover its interest payments. AMGN, with an interest coverage of 3.19, meets its interest obligations.
| Symbol | ALHC | AMGN |
|---|---|---|
| Current Ratio (TTM) | 1.69 | 1.17 |
| Quick Ratio (TTM) | 1.69 | 0.88 |
| Debt-to-Equity Ratio (TTM) | 0.07 | 9.24 |
| Debt-to-Assets Ratio (TTM) | 0.01 | 0.64 |
| Interest Coverage Ratio (TTM) | -2.98 | 3.19 |